A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

Bortezomib therapy has proven successful for the treatment of relapsed, relapsed/refractory, and newly diagnosed multiple myeloma (MM). At present, bortezomib is available as an intravenous injection, and its prolonged treatment is associated with toxicity and development of drug resistance. Here we...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Chauhan, Dharminder, Singh, Ajita V., Aujay, Monette, Kirk, Christopher J., Bandi, Madhavi, Ciccarelli, Bryan, Raje, Noopur, Richardson, Paul, Anderson, Kenneth C.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2010
Témata:
Lymphoid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3321748/
https://ncbi.nlm.nih.gov/pubmed/20805366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-04-276626
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky